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HIV-1 infection is restricted at a post-entry stage in some simian cell lines by species-specific variants of TRIM5α. Restriction targets the viral
capsid protein (CA) and results in attenuated reverse transcription. TRIM5α restriction can be inhibited by the addition of noninfectious virus-like
particles (VLPs), thus rendering cells permissive for infection by an HIV-1 reporter virus. Through the use of HIV-1 VLPs containing Gag
cleavage site substitutions and point mutations in CA which alter the stability of the viral capsid, we demonstrate that saturation of TRIM5α
restriction depends on the stability of the capsid in the incoming VLPs. Differences in the requirement for cleavage of the specific sites in Gag
were observed between distinct African green monkey cell lines. The results strongly suggest that the mechanism of HIV-1 restriction by TRIM5α
involves engagement of the viral capsid by the restriction factor prior to completion of uncoating.
© 2006 Elsevier Inc. All rights reserved.Keywords: Capsid; Uncoating; Host restriction; TRIM5α; HIV-1The immediate early events following entry of retroviruses
into target cells are poorly understood. Retroviruses gain
access to the cytoplasm by fusion of the viral and cellular
membranes either at the plasma membrane or within
endosomal compartments. The viral core, consisting of the
genomic RNA and associated proteins encased by the viral
capsid, is then released into the cytoplasm. The subsequent
steps most likely require a partial or complete disassembly of
the viral capsid in a reaction that has been referred to as
uncoating (reviewed in Dvorin and Malim, 2003; Lehmann-
Che and Saib, 2004). For HIV-1, mutations in CA that alter
capsid stability result in abortive infection and are frequently
associated with impaired reverse transcription in target cells
(Fitzon et al., 2000; Forshey et al., 2002). Even apparently
subtle alterations in the stability of the capsid, in either the
positive or negative direction, produce marked reductions in
viral infectivity. Thus, HIV-1 uncoating appears to involve a
controlled release of the viral CA protein following penetration
of the core into target cells.⁎ Corresponding author. Fax: +1 615 344 7392.
E-mail address: chris.aiken@vanderbilt.edu (C. Aiken).
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doi:10.1016/j.virol.2006.03.013HIV-1 infection is restricted at an early post-entry stage by
species-specific restriction factors that target the viral capsid
(Cowan et al., 2002; Owens et al., 2003). In rhesus macaque
and African green monkey cells, these factors are the
respective TRIM5α proteins (Hatziioannou et al., 2004;
Keckesova et al., 2004; Stremlau et al., 2004; Yap et al.,
2004). By contrast, in owl monkey cells, restriction of HIV-1
is mediated by TRIMCyp, a protein consisting of the first
three domains of TRIM5α followed by the cyclophilin A
protein (CypA) (Nisole et al., 2004; Sayah et al., 2004). As
CypA is known to associate with the viral capsid protein (CA)
(Luban et al., 1993; Yoo et al., 1997), it is plausible in
TRIM5α, engagement of CA is performed by the C-terminal
SPRY domain, which is replaced by CypA in TRIMCyp.
Consistent with this hypothesis is the observation that
substitution of SPRY by CypA preserves restriction by rhesus
TRIM5α (Yap et al., 2005).
Because restriction of HIV-1 by TRIM5α and TRIMCyp is
saturable in simian cell lines, it can be overcome by the addition
of sufficient quantities of virus-like particles (VLPs) containing
the HIV-1 Gag proteins. Thus, addition of VLPs to cells results
in enhancement of infection by a limited amount of an HIV-1
Fig. 1. Restriction of HIV-1 infection of owl monkey (OMK), rhesus macaque
(FRhK-4), and African green monkey (CV-1 and Vero) cell lines. (A) VSV-G-
pseudotyped HIV-1 reporter virus encoding GFP was titrated onto cultures of the
indicated cells, and cells were fixed 2 days later and analyzed for GFP
expression by flow cytometry. The nonlinear titration curves are indicative of
saturable host restriction of HIV-1. (B) Abrogation of restriction by HIV-1
VLPs. Cultures of the indicated cells were inoculated with a fixed, limiting
quantity of the HIV-GFP reporter virus together with the indicated doses of HIV-
1 particles lacking the GFP reporter gene. Cells were fixed 2 days later and
analyzed by flow cytometry for GFP expression. Shown are the mean values of
duplicate assays. The results are representative of three independent
experiments.
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dose of the VLPs and their sensitivity to the particular
restriction factor (Besnier et al., 2002; Cowan et al., 2002;
Kootstra et al., 2003). It also depends on specific properties of
the VLPs, including the presence of the viral protease (Cowan et
al., 2002). We previously reported an analysis of structural
aspects of the VLPs required for saturation of restriction in owl
monkey cells (Forshey et al., 2005). Using a panel of Gag
cleavage site mutants, we showed that cleavage of Gag between
MA and CAwas required for saturation. However, formation of
a conical viral capsid was not a requirement, as an HIV-1
cleavage mutant containing uncleaved CA-p2-NC protein was
fully active. Through analysis of a series of HIV-1 CA point
mutants that contain mature viral capsids of altered stability, we
observed that the potency with which HIV-1 can overcome
restriction by TRIMCyp was linked to the stability of the viral
capsid. Collectively, the results indicated that TRIMCyp
associates with a polymer of the viral CA protein and suggested
that the restriction factor engages the viral capsid prior to
completion of uncoating.
Here, we extend this analysis to HIV-1 restriction in rhesus
macaque and African green monkey cell lines, which differ
from owl monkey cells in that TRIM5α mediates restriction.
Overall, we found that the HIV-1 structural requirements for
abrogation of TRIM5α-mediated restriction are similar to those
observed for abrogation of TRIMCyp-mediated restriction in
owl monkey cells. Most significantly, abrogation of TRIM5α
restriction depends on the stability of the viral capsid in the
abrogating virus. Our results indicate that both TRIM5α and
TRIMCyp recognize an intact or partially intact HIV-1 capsid
prior to completion of uncoating.
Results
Saturability of HIV-1 restriction in owl monkey, rhesus
macaque, and African green monkey cells
HIV-1 infection of many old world monkey cell lines is
strongly restricted at an early post-entry step by TRIM5α.
Studies using chimeric viruses have clearly established that
restriction targets the CA protein, suggesting that TRIM5α may
perturb viral uncoating. To determine whether HIV-1 restriction
by TRIM5α occurs prior to disassembly of the viral capsid in
target cells, we exploited the ability of excess HIV-1 particles to
suppress restriction of an HIV-1 reporter virus when added to
target cells. Because this experimental system requires an
appropriate dose of the reporter virus, we first titrated the VSV-
pseudotyped HIV-GFP reporter virions on OMK, FRhK-4,
Vero, and CV-1 cells. In OMK cells, restriction is mediated by
TRIMCyp; by contrast, HIV-1 infection of rhesus macaque
(FRhK-4) and African green monkey (Vero and CV-1) cells is
restricted by TRIM5α. Infection of all four cells lines was
enhanced at high doses of virus (Fig. 1A), indicating that the
restrictions can be saturated by high levels of incoming virions.
Based on these titration curves, we identified the doses of
reporter virions required for infection of approximately 1% of
each cell type under these conditions. Inoculation of cells with afixed limited quantity of HIV-GFP together with increasing
doses of wild-type HIV-1 VLPs resulted in a dose-dependent
enhancement of infection by the reporter virus in all four cell
lines (Fig. 1B). Infection was roughly linear with input virus
dose, indicating that the assay can be used to quantify the ability
of mutant HIV-1 particles to abrogate restriction in the four cell
lines.
Assays of the fusion ability of mutant HIV-1 particles
pseudotyped by VSV-G
To generate VSV-G-pseudotyped HIV-1 particles for
studies of saturation of restriction, we produced virions
that could also be assayed for fusion with target cells to
ensure that differences in viruses resulted not from impaired
virus entry but rather from post-entry effects. For this
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an expression construct encoding BlaM-Vpr. The fusion
protein is specifically incorporated into HIV-1 particles via
interaction of the Vpr portion with Gag during assembly.
During maturation, the viral protease cleaves BlaM-Vpr,
resulting in activation of BlaM. Upon fusion of the resulting
particles with target cells, active BlaM is released into the
cytoplasm, where it can be detected following loading of the
cells with the fluorogenic substrate CCF2-AM (Zlokarnik et
al., 1998). By quantifying the fluorescence of the cells at
two wavelengths, the extent of fusion can be determined.
The resulting signal is dependent on the extent of virus–cell
fusion, since it requires a functional Env protein and is
blocked by specific inhibitors of HIV-1 fusion (Jiang and
Aiken, 2005; Wyma et al., 2004). Assays of the virus stocks
with SupT1 target cells demonstrated that the fusion of allFig. 2. Analysis of the entry capacity of mutant viruses used for abrogation assays. V
together with plasmids encoding a BlaM-Vpr fusion protein as well as VSV-G. (A) Vi
cell fusion. (B) Particles were pelleted, and virus lysates were analyzed by immuno
(bottom panel). The monoclonal antibody used to detect Ca does not react with theof the VSV-pseudotyped viral mutants fused at levels similar
to wild type (Fig. 2A). As expected, virions lacking VSV-G
exhibited only background signals in the assay (Fig. 2A). To
determine whether the interpretation of the fusion results
could be misleading due to unequal packaging or cleavage
of BlaM-Vpr, we analyzed the viral particles by immuno-
blotting. The BlaM-Vpr and cleaved BlaM levels were
similar for all of the viruses, but the VSV-G levels varied
significantly in the virus lysates (Fig. 2B). We have
observed that cells expressing VSV-G release large quanti-
ties of vesicles containing the glycoprotein into culture
supernatants, possibly accounting for the variability in the
VSV-G levels among the virus samples. The equivalent
fusion activity observed with these stocks of viruses
indicated that they were suitable for quantitative studies of
saturation of restriction.iruses were produced by cotransfection of Env-defective mutant proviral clones
ruses were tested for fusion on SupT1 cells using the BlaM assay of HIV-1 virus–
blotting using antibodies to BlaM (top panel), VSV-G (middle panel), and CA
K170 mutant protein.
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TRIM5α-mediated restriction
In a previous study, we reported that cleavage of Gag
between MA and CA is essential for HIV-1 to saturate
restriction by TRIMCyp. This result suggested that proper
folding of the β-hairpin at the amino terminus of CA is required
for recognition of the viral capsid by TRIMCyp. To determine
whether TRIM5α restriction also depends on release of MA, we
tested the ability of HIV-1 mutants containing substitutions at
specific cleavage sites in Gag to overcome restriction in rhesus
macaque and African green monkey cells. The MA/CA and
MA/NC viruses both contain a mutation preventing cleavage at
the MA-CA junction. These mutants were impaired in the
ability to saturate restriction in all four simian cell lines (Fig.
3A). However, some residual activity was detected in the Vero
and CV1 cell lines, suggesting that the cleavage enhances
recognition but is not strictly required to overcome restriction
by TRIM5α in these African green monkey cell lines. These
results indicate that cleavage of the MA-CA junction is required
for efficient saturation of TRIM5α restriction of HIV-1, though
it may not represent an absolute requirement in CV-1 cells.
To determine whether release of NC is required for HIV-1 to
saturate restriction by TRIM5α, we analyzed two mutants
containing substitutions at the CA-p2 and p2-NC cleavage sites.
CA/p2 encodes substitutions preventing cleavage of the CA-p2
junction, while CA/NC is not cleaved at any of the sites between
CA and NC. As previously reported for OMK cells, the CA/p2
mutant was markedly impaired in the ability to overcome
restriction in the FRhK-4, Vero, and CV1 cell lines (Fig. 3A).
By contrast, the activity of CA/NCmutant virions was similar to
wild-type virions in OMK, FRhK-4, and CV1 cells, but their
potency was reduced in Vero cells (Fig. 3A). CA/NC virions,
though immature, contain stable cores most likely due to the
association of the CA-p2-NC molecules with viral RNA. These
results suggest that requirements for recognition of the viral
capsid by TRIM5α differ in Vero and CV1 cells, a conclusion
that is supported by the reported differences in specificity of
restriction exhibited by TRIM5α proteins from different
subspecies of African green monkeys (Hatziioannou et al.,
2003; Song et al., 2005).
Abrogation of TRIM5α-mediated restriction depends on the
stability of the HIV-1 capsid
While the CA/p2 mutant was impaired for saturation of
restriction in all cell lines tested, the CA/NC was fully active in
three of four of the lines. Analysis of these mutant particles
following treatment with nonionic detergent has shown that the
CA/p2 particles have unstable capsids, while the CA/NC
particles are relatively detergent-resistant (Wiegers et al., 1998).
In our previous study of the requirements for saturation in OMK
cells, the activity was linked to formation of a stable viral capsid
(Forshey et al., 2005). To determine whether this requirement
extends to restriction by TRIM5α, we analyzed the ability of
HIV-1 mutants containing substitutions in CA that were
previously shown to alter the stability of the capsid withoutaffecting Gag processing or core formation (Forshey et al.,
2002). The P38A, K170A, and K203A mutants result in
unstable capsids, while the E45A mutation results in elevated
stability relative to wild type. Overall, the ability of these
mutants to saturate restriction in FRhK-4, Vero, and CV1 cells
was qualitatively similar to that previously observed for OMK
cells (Fig. 3B). The mutants with unstable capsids (K170A and
K203A) were less potent than wild type in all cell lines. The
P38A mutant, which is also reduced in capsid stability, showed
an intermediate ability to saturate restriction in FRhK-4, Vero,
and CV-1 (Fig. 3B). By contrast, the hyperstable E45A mutant
was more active than wild type in three out of four of the lines.
As with the MA/CA and MA/NC mutants, Vero cells were the
exception, with E45A exhibiting a decreased ability to saturate
restriction relative to wild type (Fig. 3B). The results suggest
that the E45A mutant capsid might be poorly recognized by
Vero cell TRIM5α. Overall, the results indicate that a stable
viral capsid is necessary but not sufficient for efficient
saturation of TRIM5α-dependent restriction. They further
underscore the differences in specificity of TRIM5α proteins
from subspecies of African green monkeys.
Analysis of the CA point mutants demonstrated an overall
positive correlation between saturation of restriction and capsid
stability. However, it remained possible that the CA mutants
containing unstable capsids were impaired for abrogation due to
the effects of the substitutions on recognition and not as a
consequence of the effects of these mutations on capsid
stability. To distinguish between these possibilities, we
exploited the ability of the CA/NC cleavage mutant to saturate
TRIM5α-mediated restriction. For this purpose, the CA point
mutations were transferred into the CA/NC mutant background,
and the resulting virions were tested for their ability to saturate
restriction in all of the cell lines. As previously reported
(Forshey et al., 2005), addition of the CA/NC cleavage site
mutations relieved the inhibitory effects of the P38A, K170A,
and K203A substitutions on saturation of restriction in OMK
cells (Fig. 3C). However, the E45A mutant, which contains
stable cores, was not enhanced by addition of the CA/NC
cleavage site mutations. Similar results were observed with
these mutants in FRhK-4, Vero, and CV-1 cells (Fig. 3C). The
CA/NC-P38A mutant was somewhat less active in CV-1 cells
than the other mutants, thus suggesting that this mutant may be
poorly recognized in this specific cell line (Fig. 3C).
Collectively, these results argue against the existence of a
direct recognition defect for the P38A, K170A, and K203A
mutants and support the conclusion that saturation of TRIM5α
restriction depends on a stable viral capsid.
Discussion
Uncoating of the viral core following penetration into target
cells remains a fundamentally obscure stage of retrovirus
infection. Nonetheless, this stage is of critical importance for
reverse transcription in target cells. Mutations in CA that alter
the stability of the HIV-1 capsid lead to poor infectivity and, in
most cases, attenuated reverse transcription (Forshey et al.,
2002). Although HIV-1 uncoating can be studied in vitro,
Fig. 3. Assays of the ability of HIV-1 particles to enhance infection by HIV-GFP reporter virions in simian cell lines. Cells were inoculated with a fixed limited quantity
of HIV-GFP with various doses of the indicated mutant viruses lacking GFP. For the K170A mutant, virus dose was normalized to wild type by reverse transcriptase
activity. The remaining virus stocks were normalized for p24 content. For simplicity, the figure shows only the values corresponding to a fixed dose (50 ng p24) of the
respective abrogating virions. (A) Assays of viruses containing cleavage site mutations in Gag cleavage sites. (B) Assays of viruses containing point mutations in CA.
(C) Assays of viruses containing point mutations in CA as well as CA/NC cleavage site mutations. Results shown are representative of three independent experiments,
all of which yielded similar results.
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not yet been established. Because the HIV-1 restriction factors
TRIM5α and TRIMCyp specifically recognize the viral CA
protein, it is expected that studies of the mechanism by which
these factors inhibit HIV-1 infection will yield insights into the
process of uncoating.
TRIM5α and TRIMCyp restrict HIV-1 infection at an early
post-entry stage leading to impaired reverse transcription.
Although the mechanism is yet to be defined, a plausible
model for restriction involves engagement of the viral capsid by
the factor and either destruction or impaired uncoating of the
core. HIV-1 infection is inhibited by mutations that result in
small changes in capsid stability in vitro, suggesting that
uncoating is a step that is precisely balanced and therefore
highly sensitive to inhibitors. In this study, we tested the
hypothesis that the TRIM5α proteins from rhesus macaque and
African green monkey cells recognize an intact viral capsid
prior to uncoating. By testing Gag cleavage site mutants and CA
point mutants exhibiting altered capsid stability in vitro, we
demonstrated a correlation between the potency with which
HIV-1 particles overcome TRIM5α-mediated restriction and the
stability of the viral capsid. Two mutant viruses, K170A and
K203A, which exhibit unstable capsids in vitro, were markedly
impaired in their ability to saturate restriction in rhesus
macaque, African green monkey, and owl monkey cells.
Activity was restored to these CA mutants by addition of
substitutions preventing cleavage of the CA-p2-NC region of
Gag. Because these mutations result in formation of stable
“capsids” likely via tethering of CA to viral RNA via the NC
region of Gag, the restoration of activity resulting from the
cleavage site mutations indicates that the failure of the K170A
and K203A mutants to saturate restriction is owing to poor
capsid stability and not to a direct effect of the CA mutations on
recognition by TRIM5α. Together, these results argue strongly
that TRIM5α engages an intact or semi-intact viral capsid prior
to completion of uncoating in target cells. Thus, TRIM5α and
TRIMCyp, despite having markedly different recognition
domains, appear to share a requirement for multivalent
interactions with the incoming viral capsid.
In addition to the requirement for a stable capsid, saturation
of TRIM5α restriction was also dependent on cleavage of the
MA-CA junction by the viral protease. This was previously
observed for HIV-1 restriction in OMK cells and suggests that
proper folding of the amino terminal region of CA is essential
for recognition by the restriction factors. In our previous study,
we showed that point mutations predicted to inhibit proper
folding of the β-hairpin domain in CA resulted in an inability to
saturate restriction by TRIMCyp (Forshey et al., 2005).
Addition of the CA/NC cleavage site substitutions to these
mutants did not restore activity, suggesting that the point
mutations in the β-hairpin domain resulted in a direct
recognition defect independent of effects on capsid stability.
Although the β-hairpin mutants have not yet been assayed for
effects on TRIM5α-mediated restriction, we expect that they
will prove to be defective.
Interestingly, the P38A mutant, which also exhibits unstable
capsids in vitro (Forshey et al., 2002), was less impaired forsaturation of restriction in the rhesus macaque and African
green monkey lines than in owl monkey cells. Although the
basis for this apparent cell type-dependent difference remains
unclear, it seems possible that the in vitro assay may not
completely describe HIV-1 capsid stability in target cells. The
method used to determine capsid stability in vitro involves
treatment of virions with detergent followed by equilibrium
density gradient sedimentation and thus requires the capsid to
remain intact for 14 h or more prior to detection. We thus
speculate that the biochemical assay may be a more stringent
test of capsid stability than what actually occurs in target cells. It
is also possible that cells differ with respect to expression of
host factors that influence HIV-1 uncoating. The recent
description of a human cell HIV-1 uncoating activity that is
induced upon activation of T cells is consistent with this
hypothesis (Auewarakul et al., 2005).
The conclusion that the ability of HIV-1 particles to
saturate restriction depends on the stability of the viral capsid
suggests that TRIM5α forms a complex with the viral core
that is dependent on multivalent interactions with CA.
Consistent with this hypothesis, Mische and coworkers
have shown that TRIM5α and TRIMCyp can be chemically
cross-linked into trimers and oligomers of higher order,
implying that TRIM5 restriction factors exist as oligomers in
their native state (Mische et al., 2005). These findings also
support a model in which TRIM5 restriction factors, via their
coiled coil domains, form oligomers that bind directly to
HIV-1 capsids in target cells. According to this model,
accelerated uncoating, as observed with the K170A and
K203A mutants, results in rapid dissociation of CA. Because
the restriction factors may not form stable complexes with
monomeric CA, the soluble CA released from the unstable
capsids does not result in sequestration of TRIM5α, and thus,
the mutants fail to overcome restriction. In support of this
latter assertion, it has recently been shown that expression of
fully processed CA in target cells does not suppress
TRIM5α-mediated restriction of murine leukemia virus
(Dodding et al., 2005).
Saturation of restriction is a powerful genetic assay for
studying the requirements for restriction. Although the
mechanism by VLPs abrogate restriction is not fully elucidated,
we imagine three possibilities. In the first scenario, the
incoming viral capsids form a stable complex with the
restriction factor, leading to its (potentially reversible) seques-
tration. Second, engagement of the viral capsid by restriction
factors may lead to degradation of the complex in target cells.
This degradation might involve TRIM5α-dependent modifica-
tion of the viral capsid in a catalytic fashion, perhaps via
ubiquitylation catalyzed by the RING domain of the restriction
factor. The restriction factor may then dissociate prior to
degradation of the core, allowing it to act on another viral
capsid. In the third scenario, the restriction factor remains
associated with the viral core and is degraded along with it.
Because TRIM5 restriction factors contain a RING domain that
is characteristic of a class of ubiquitin ligases, TRIM5α and
TRIMCyp may induce ubiquitylation of the viral capsid
resulting in its degradation by the proteasome. However,
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restriction (Perez-Caballero et al., 2005). Additional studies of
the requirements for saturation of restriction are likely to reveal
new insights into the mechanism of TRIM5α-mediated
restriction itself.
Materials and methods
Cell lines
The OMK, FRhK-4, Vero, and CV-1 cells used in this study
were purchased from the American Type Culture Collection.
293T cells were a gift from Inder Verma, and SupT1 cells were
obtained from the NIH AIDS Research and Reference Reagent
Program. All lines except SupT1 were cultured in Dulbecco's
modification of Eagle's medium (Cellgro) supplemented with
fetal bovine serum (10%), penicillin (50 IU/ml), and strepto-
mycin (50 μg/ml). SupT1 cells were cultured in RPMI1640
medium with the same supplements. Cells were cultured in a
humidified 37 °C incubator containing 5% CO2.
Viruses
Proviral constructs used in this study were derived from the
pNL4-3 and pR9 full-length proviruses containing intact open
reading frames for all viral accessory genes (Adachi et al.,
1986; Gallay et al., 1997). All proviruses used in this study
encoded a frameshift at the NdeI restriction site in env,
resulting in Env-deficient particles. The HIV-GFP plasmid,
encoding the green fluorescent protein in place of Nef, was a
gift from D. Gabuzda and has been described (He et al.,
1997). The Gag cleavage site mutants MA/CA, MA/NC, CA/
p2 (previously named CA5), and CA/NC (previously named
CA6) were generated in pNL4-3 as previously described
(Wiegers et al., 1998; Wyma et al., 2004). The P38A, E45A,
K170A, and K203A CA mutants in pR9 have been described
(Forshey et al., 2002; von Schwedler et al., 2003), as have the
CA/NC-P38A, CA/NC-E45A, and CA/NC-K203A mutants in
the pNL4-3 background (Forshey et al., 2005). CA/NC-
K170A was created for use in this study by PCR segment
overlap extension of the K170A mutation onto the Gag
cleavage site mutations in CA/NC. The resulting PCR
product, containing both CA/NC and K170A substitutions,
was first ligated into the CA/NC-ΔEΔN proviral construct,
generating CA/NC-K170A-ΔEΔN. The BssHII-EcoRI frag-
ment from this plasmid was then transferred into CA6-ΔE to
generate CA/NC-K170A. VSV-G-pseudotyped virus particles
were produced by calcium phosphate cotransfection of 293T
cells with 20 μg of proviral DNA and 3 μg of pHCMV-G
(Yee et al., 1994). Viruses were harvested 24 h after
transfection, clarified through 0.45-μm cellulose acetate filters,
and frozen and stored in aliquots at −80 °C. Virus stocks were
assayed for p24 concentration by ELISA after boiling samples
in 1% SDS to solubilize Gag proteins. For HIV-1 mutants
containing the K170A substitution, virus stocks were assayed
for reverse transcriptase activity as previously described
(Aiken and Trono, 1995). These virus stocks were normalizedagainst wild type by RT activity in assays of abrogation of
restriction.
Assay of HIV-1 fusion
The fusion of HIV-1 particles with SupT1 target cells was
measured as previously described (Wyma et al., 2004). Briefly,
reporter viruses were produced by cotransfection of proviral
DNA (20 μg) with pHCMV-G (3 μg) and pMM310 (7 μg),
which encodes a fusion protein consisting of the E. coli β-
lactamase (BlaM) attached to the amino terminus of HIV-1 Vpr.
Virus stocks were normalized for p24 (or RT in the case of K170
mutants) concentration by dilution with complete medium, and
aliquots (100 μl) of diluted viruses were added to SupT1 cells
(100,000) in black-walled microtiter plates with transparent
culture surface. Cultures were incubated at 37 °C for 2 h,
followed by loading with the cell-permeable BlaM substrate
CCF2-AM (PanVera) overnight at room temperature in the
dark. The cells were then pelleted by centrifuging the plates, and
the medium was replaced with 100 μl of PBS. The fluorescence
was measured from the bottom at 450 nm and 520 nm after
excitation at 410 nm in a BMG FLUOstar fluorometer. Because
cleavage of CCF2-AM by BlaM results in an emission spectral
shift from 520 to 450 nm, the extent of fusion was calculated as
the emission signal at 450 nm divided by that at 520 nm, after
subtraction of the appropriate background values.
Immunoblotting of viral particles
Virus particles were pelleted at 100,000×g for 30 min and
solubilized in SDS-PAGE sample buffer. Samples (corresponding
to 700 ng of p24) were heated at 95 °C for 5 min and loaded on
BioRad Criterion precast 4–20% polyacrylamide gradient gels.
Following electrophoresis, proteins were transferred to PVDF a
membrane and blocked in 5% nonfat dry milk in Tris-buffered
saline. Blots were probes with mouse anti-BlaM (Sigma), rabbit
anti-VSV-G (Sigma), and mouse anti-CA (from Bruce Chesebro)
followed by the appropriate infrared dye-coupled secondary
antibodies. Bands were detected by infrared emission using the
LI-Cor Odyssey imaging system and quantified using the
instrument software.
Assays of HIV-1 infection
VSV-pseudotyped HIV-GFP reporter particles were titrated
onto each cell line to determine the appropriate dose for use in
assays of restriction. Saturation of restriction assays were
performed essentially as described (Forshey et al., 2005)
Briefly, cells (20,000) were plated in 24-well plates 1 day
prior to inoculation with a limited fixed quantity of HIV-GFP
virions together with various doses of abrogating virions. Two
days after inoculation, cells were detached using trypsin and
fixed in a freshly prepared solution of PBS containing 4%
paraformaldehyde. The next day, cells were analyzed for GFP
expression by flow cytometry using a Becton-Dickinson
FACScalibur. Values were reported as the percentage of GFP+
cells in the cultures.
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